NYMX Nymox Pharmaceutical Corp

This press release is being disseminated as required by the early warning requirements of applicable Canadian securities laws. Paul Averback MD of 9900 Cavendish Blvd. Suite 306, St-Laurent, Quebec, announces today that he has sold in a private transaction for financial planning purposes 465,000 common shares of Nymox Pharmaceutical Corporation ("Nymox") for a total consideration of $2,032,092 ($1,999,500 US). The sale represents approximately 1.38 % of the shares of Nymox issued and outstanding. Dr. Averback has no further intention to acquire or sell securities of the Corporation at this time. As a result of this sale, Dr. Averback continues to own and control 11,774,914 shares of Nymox or approximately 34.9 % of the shares of Nymox issued and outstanding. An additional 607,031 shares of Nymox (approximately 1.8 %) are owned by a family trust of which Dr. Averback is a trustee. Dr. Averback is subject to the early warning requirements for this transaction because he is a control person of Nymox by virtue of the fact that he owns more than 20% of the outstanding shares of Nymox. The sale relies on the prospectus exemption contained in Section 2.3 of Regulation 45-106 - Prospectus and Registration Exemptions. Nymox's common shares are listed on the NASDAQ Exchange under the symbol "NYMX".

CONTACT: Paul Averback
         Tel: (514) 332-3222